In vivo, adapalene at dosages of 15 to 100 mg/kg administered orally daily for 21 days inhibits the growth of DLD1 cell-derived xenograft tumors in BALB/C nude mice, highlighting its potential for clinical use in cancer therapy^[3].

In cell viability assays, adapalene impacts several cancer cell lines, reducing the viability of ES-2, HOV-7, MCF-7, Hela, SW1990, HT1080, and MM-468 cells. The IC50 values range from 10.36 μM for ES-2 cells to 31.47 μM for MM-468 cells over a 24-hour treatment period at concentrations between 1 and 200 μM^[2].

In further experiments, adapalene at 10-40 μM induces apoptosis and inhibits the proliferation of ES-2 cells in vitro^[2].

Adapalene also affects cell cycle distribution, significantly increasing the G1-phase population in LoVo and DLD1 cells when applied in concentrations ranging from 3 to 30 μM over periods of 6 to 24 hours^[3].

Additionally, adapalene demonstrates inhibition of GOT1 activity with an IC50 of 21.79 μM^[2].

Otherwise, Adapalene also effectively suppresses the expression of transglutaminase Type I, a plasma membrane-associated enzyme, with an IC50 of 2.5 nM at concentrations from 10^-6 -10^-3 nM^[1].